Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Umang Swami

Showing results (121-130 of 170) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2022
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate CancerUmang Swami, Ryon P Graf, Roberto H Nussenzveig, et al.
European Urology|July 7, 2020
Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate CancerUmang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al.
The Oncologist|June 22, 2021
Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning PlatformEdwin Lin, Andrew W Hahn, Roberto H Nussenzveig, et al.
Kidney Cancer (Clifton, Va.)|September 12, 2024
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based CombinationsArshit Narang, Georges Gebrael, Yeonjung Jo, et al.
Urology Practice|October 30, 2023
Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway InhibitorsGeorges Gebrael, Nicolas Sayegh, Nishita Tripathi, et al.
Frontiers in Immunology|September 6, 2023
A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcomeJohn Marsiglio, Jordan P McPherson, Magdalena Kovacsovics-Bankowski, et al.
Urology Practice|October 31, 2023
Reply by AuthorsGeorges Gebrael, Nicolas Sayegh, Nishita Tripathi, et al.
European Urology Oncology|November 9, 2024
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216Umang Swami, Yeonjung Jo, Arshit Narang, et al.
Journal of Kidney Cancer and VHL|April 30, 2025
First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell CarcinomaMicah Ostrowski, Yeonjung Jo, Georges Gebrael, et al.
JAMA Network Open|July 9, 2024
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 TrialGeorges Gebrael, Yeonjung Jo, Umang Swami, et al.
Pageof 17

Showing results (121-130 of 170) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2022
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate CancerUmang Swami, Ryon P Graf, Roberto H Nussenzveig, et al.
European Urology|July 7, 2020
Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate CancerUmang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al.
The Oncologist|June 22, 2021
Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning PlatformEdwin Lin, Andrew W Hahn, Roberto H Nussenzveig, et al.
Kidney Cancer (Clifton, Va.)|September 12, 2024
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based CombinationsArshit Narang, Georges Gebrael, Yeonjung Jo, et al.
Urology Practice|October 30, 2023
Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway InhibitorsGeorges Gebrael, Nicolas Sayegh, Nishita Tripathi, et al.
Frontiers in Immunology|September 6, 2023
A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcomeJohn Marsiglio, Jordan P McPherson, Magdalena Kovacsovics-Bankowski, et al.
Urology Practice|October 31, 2023
Reply by AuthorsGeorges Gebrael, Nicolas Sayegh, Nishita Tripathi, et al.
European Urology Oncology|November 9, 2024
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216Umang Swami, Yeonjung Jo, Arshit Narang, et al.
Journal of Kidney Cancer and VHL|April 30, 2025
First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell CarcinomaMicah Ostrowski, Yeonjung Jo, Georges Gebrael, et al.
JAMA Network Open|July 9, 2024
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 TrialGeorges Gebrael, Yeonjung Jo, Umang Swami, et al.
Pageof 17